# Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide

> **NCT02120638** · PHASE3 · UNKNOWN · sponsor: **Huashan Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Multidrug Resistant Tuberculosis

## Interventions

- **DRUG:** Pyrazinamide containing regimen
- **DRUG:** Regimen without Pyrazinamide

## Key facts

- **NCT ID:** NCT02120638
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-04
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2014-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02120638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02120638, "Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02120638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*